Biohaven Ltd. received a partial clinical hold from the FDA on September 4, 2026, pausing new patient enrollment in its BHV-7000 program for refractory focal epilepsy due to insufficient nonclinical data regarding a specific metabolite observed in rodent testing. The hold applies only to new enrollment; dosing continues for over 600 already randomized patients across the program. Study BHV7000-303 is fully enrolled, with topline data expected in the second half of 2026. On August 26, 2026, Biohaven Bioscience Ireland Limited entered into a license agreement with SK Biopharmaceuticals Co., Ltd., granting an exclusive, royalty-bearing worldwide license to its Kv7 ion channel platform, including BHV-7000, pending HSR clearance. The company operates in the biotechnology industry, focusing on developing treatments for neurological disorders.

On August 26, 2026, Biohaven Ltd. entered into a strategic global licensing agreement with SK Biopharmaceuticals Co., Ltd. granting an exclusive worldwide license to its Kv7 ion channel platform, led by opakalim (BHV-7000), for the treatment of focal epilepsy. SKBP will pay a non-refundable upfront fee of $400 million ($350 million at closing and $50 million in 2027) and is eligible to pay up to $150 million in development and regulatory milestones. Biohaven retains rights to conduct ongoing Phase 2/3 clinical trials (RISE 2 and RISE 3) for opakalim, while SKBP assumes responsibility for future development costs and certain milestone obligations totaling $245 million tied to Knopp Biosciences. The transaction includes tiered royalties ranging from the mid-teens to low twenties on U.S. net sales and mid-single-digit royalties on ex-U.S. sales. Biohaven Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing treatments for immunology, neuroscience, and oncology.

Biohaven Ltd. reported financial results for the second quarter ended June 30, 2026, posting a net loss of $137.3 million, or $0.91 per share, compared to a net loss of $198.1 million in the prior year period. Research and development expenses decreased to $100.8 million from $184.4 million due to strategic reprioritization and lower one-time milestone payments. The company reported cash, cash equivalents, marketable securities, and restricted cash totaling approximately $270.5 million as of June 30, 2026. Clinically, Biohaven initiated a pivotal Phase 3 study for BHV-1300 in Graves' disease and plans to initiate a pivotal Phase 3 trial for BHV-1400 in IgA nephropathy during the second half of 2026. The company also announced new clinical data for its oncology candidate BHV-1530 and completed enrollment in a Phase 2 obesity study for taldefgrobep alfa. Biohaven Ltd. is a global clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for rare and common diseases.

Biohaven Ltd. appointed John Yetimoglu as a director effective August 6, 2026, to serve in the class expiring at the 2027 Annual Meeting of Shareholders. He was also named to the Nominating and Governance Committee. His compensation includes options with an aggregate grant date fair value of $713,875 vesting over four years and a $57,000 annual retainer. Biohaven Ltd. is a biopharmaceutical company focused on developing treatments for neurological disorders.

Biohaven Ltd. announced scientific leadership transitions effective July 13, 2026, where Dr.. Bruce Car will retire as Chief Scientific Officer and transition to a part-time role as Chief Innovation Officer, resulting in a 50% salary reduction. Concurrently, David Pirman, Ph.D., has been promoted to Executive Vice President and Head of Discovery to lead the internal drug-discovery organization. Biohaven Ltd. operates in the biotechnology industry, focusing on the development of novel therapeutic solutions.